Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer

American Journal of Pathology

Volumn 184, Issue 9, 2014, Pages 2390-2402

  Daikoku, Takiko ^a   Terakawa, Jumpei ^a   Hossain, Md M ^a   Yoshie, Mikihiro ^a   Cappelletti, Monica ^a   Yang, Peiying ^b   Ellenson, Lora H ^c   Dey, Sudhansu K ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; ESTROGEN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROGESTERONE; RAPAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; CYCLOOXYGENASE 2 INHIBITOR; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PYRAZOLE DERIVATIVE; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DISEASE EXACERBATION; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOLOCALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; CARCINOMA; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; ENDOMETRIUM TUMOR; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA; CELECOXIB; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 84906237080     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.05.023     Document Type: Article

References (52)

1. A. Di Cristofano, and L.H. Ellenson Endometrial carcinoma Annu Rev Pathol 2 2007 57 85
2. B. Weigelt, and S. Banerjee Molecular targets and targeted therapeutics in endometrial cancer Curr Opin Oncol 24 2012 554 563
3. M.E. St-Germain, V. Gagnon, I. Mathieu, S. Parent, and E. Asselin Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells Int J Oncol 24 2004 1311 1324
4. H. Sheng, J. Shao, and R.N. Dubois K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1 Cancer Res 61 2001 2670 2675
5. J. Shao, H. Sheng, H. Inoue, J.D. Morrow, and R.N. DuBois Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells J Biol Chem 275 2000 33951 33956
6. N. Pommery, and J.P. Henichart Involvement of PI3K/Akt pathway in prostate cancer-potential strategies for developing targeted therapies Mini Rev Med Chem 5 2005 1125 1132
7. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22
8. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 2009 627 644
9. B.M. Slomovitz, and R.L. Coleman The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer Clin Cancer Res 18 2012 5856 5864
10. A. Gadducci, R. Tana, S. Cosio, A. Fanucchi, and A.R. Genazzani Molecular target therapies in endometrial cancer: from the basic research to the clinic Gynecol Endocrinol 24 2008 239 249
11. J.H. No, Y.T. Jeon, I.A. Park, D. Kang, J.W. Kim, N.H. Park, S.B. Kang, and Y.S. Song Expression of mTOR protein and its clinical significance in endometrial cancer Med Sci Monit 15 2009 BR301 BR305
12. A. Nasir, D. Boulware, H.E. Kaiser, J.M. Lancaster, D. Coppola, P.V. Smith, A. Hakam, S.E. Siegel, and B. Bodey Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy In Vivo 21 2007 35 43
13. B.J. Tong, J. Tan, L. Tajeda, S.K. Das, J.A. Chapman, R.N. DuBois, and S.K. Dey Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma Neoplasia 2 2000 483 490
14. H. Toyoki, J. Fujimoto, E. Sato, H. Sakaguchi, and T. Tamaya Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in uterine endometrial cancers Ann Oncol 16 2005 51 55
15. D. Wang, and R.N. Dubois Eicosanoids and cancer Nat Rev Cancer 10 2010 181 193
16. M.E. Turini, and R.N. DuBois Cyclooxygenase-2: a therapeutic target Annu Rev Med 53 2002 35 57
17. T. Daikoku, Y. Hirota, S. Tranguch, A.R. Joshi, F.J. DeMayo, J.P. Lydon, L.H. Ellenson, and S.K. Dey Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice Cancer Res 68 2008 5619 5627
18. S.M. Soyal, A. Mukherjee, K.Y. Lee, J. Li, H. Li, F.J. DeMayo, and J.P. Lydon Cre-mediated recombination in cell lineages that express the progesterone receptor Genesis 41 2005 58 66
19. T. Daikoku, M. Yoshie, H. Xie, X. Sun, J. Cha, L.H. Ellenson, and S.K. Dey Conditional deletion of Tsc1 in the female reproductive tract impedes normal oviductal and uterine function by enhancing mTORC1 signaling in mice Mol Hum Reprod 19 2013 463 472
20. J. Reese, X. Zhao, W.G. Ma, N. Brown, T.J. Maziasz, and S.K. Dey Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice Endocrinology 142 2001 3198 3206
21. Y. Hirota, T. Daikoku, S. Tranguch, H. Xie, H.B. Bradshaw, and S.K. Dey Uterine-specific p53 deficiency confers premature uterine senescence and promotes preterm birth in mice J Clin Invest 120 2010 803 815
22. T. Daikoku, D. Wang, S. Tranguch, J.D. Morrow, S. Orsulic, R.N. DuBois, and S.K. Dey Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer Cancer Res 65 2005 3735 3744
23. Y. Hirota, J. Cha, M. Yoshie, T. Daikoku, and S.K. Dey Heightened uterine mammalian target of rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice Proc Natl Acad Sci U S A 108 2011 18073 18078
24. P.S. Tanwar, L. Zhang, T. Kaneko-Tarui, M.D. Curley, M.M. Taketo, P. Rani, D.J. Roberts, and J.M. Teixeira Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt[beta]/catenin and PTEN PLoS One 6 2011 e20715
25. P. Gulhati, Y.Y. Zaytseva, J.D. Valentino, P.D. Stevens, J.T. Kim, T. Sasazuki, S. Shirasawa, E.Y. Lee, H.L. Weiss, J. Dong, T. Gao, and B.M. Evers Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA Carcinogenesis 33 2012 1782 1790
26. N. Lee, C.L. Woodrum, A.M. Nobil, A.E. Rauktys, M.P. Messina, and S.L. Dabora Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models BMC Pharmacol 9 2009 8
27. Z. Wang, J. Zhou, J. Fan, S.J. Qiu, Y. Yu, X.W. Huang, and Z.Y. Tang Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma Clin Cancer Res 14 2008 5124 5130
28. S.M. Stepkowski Preclinical results of sirolimus treatment in transplant models Transplant Proc 35 3 Suppl 2003 219S 226S
29. Z.J. Sun, L. Zhang, B. Hall, Y. Bian, J.S. Gutkind, and A.B. Kulkarni Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model Clin Cancer Res 18 2012 5304 5313
30. T. Daikoku, S. Tranguch, D.B. Friedman, S.K. Das, D.F. Smith, and S.K. Dey Proteomic analysis identifies immunophilin FK506 binding protein 4 (FKBP52) as a downstream target of Hoxa10 in the periimplantation mouse uterus Mol Endocrinol 19 2005 683 697
31. Y. Tan, M. Li, S. Cox, M.K. Davis, O. Tawfik, B.C. Paria, and S.K. Das HB-EGF directs stromal cell polyploidy and decidualization via cyclin D3 during implantation Dev Biol 265 2004 181 195
32. K. Kover, L. Liang, G.K. Andrews, and S.K. Dey Differential expression and regulation of cytokine genes in the mouse uterus Endocrinology 136 1995 1666 1673
33. T. Daikoku, J. Cha, X. Sun, S. Tranguch, H. Xie, T. Fujita, Y. Hirota, J. Lydon, F. DeMayo, R. Maxson, and S.K. Dey Conditional deletion of Msx homeobox genes in the uterus inhibits blastocyst implantation by altering uterine receptivity Dev Cell 21 2011 1014 1025
34. T. Daikoku, S. Tranguch, I.N. Trofimova, D.M. Dinulescu, T. Jacks, A.Y. Nikitin, D.C. Connolly, and S.K. Dey Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer Cancer Res 66 2006 2527 2531
35. P. Yang, D. Chan, E. Felix, T. Madden, R.D. Klein, I. Shureiqi, X. Chen, A.J. Dannenberg, and R.A. Newman Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids Prostaglandins Leukot Essent Fatty Acids 75 2006 385 395
36. T. Daikoku, S. Tranguch, A. Chakrabarty, D. Wang, D. Khabele, S. Orsulic, J.D. Morrow, R.N. Dubois, and S.K. Dey Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer Cancer Res 67 2007 5285 5292
37. S.C. Johnson, P.S. Rabinovitch, and M. Kaeberlein mTOR is a key modulator of ageing and age-related disease Nature 493 2013 338 345
38. Y. Ding, M. Tong, S. Liu, J.A. Moscow, and H.H. Tai NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer Carcinogenesis 26 2005 65 72
39. Z. Liu, X. Wang, Y. Lu, S. Han, F. Zhang, H. Zhai, T. Lei, J. Liang, J. Wang, K. Wu, and D. Fan Expression of 15-PGDH is downregulated by COX-2 in gastric cancer Carcinogenesis 29 2008 1219 1227
40. M. Yan, S.J. Myung, S.P. Fink, E. Lawrence, J. Lutterbaugh, P. Yang, X. Zhou, D. Liu, R.M. Rerko, J. Willis, D. Dawson, H.H. Tai, J.S. Barnholtz-Sloan, R.A. Newman, M.M. Bertagnolli, and S.D. Markowitz 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors Proc Natl Acad Sci U S A 106 2009 9409 9413
41. S. Darb-Esfahani, A. Faggad, A. Noske, W. Weichert, A.C. Buckendahl, B. Muller, J. Budczies, A. Roske, M. Dietel, and C. Denkert Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro J Cancer Res Clin Oncol 135 2009 933 941
42. Z. Chen, L.C. Trotman, D. Shaffer, H.K. Lin, Z.A. Dotan, M. Niki, J.A. Koutcher, H.I. Scher, T. Ludwig, W. Gerald, C. Cordon-Cardo, and P.P. Pandolfi Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis Nature 436 2005 725 730
43. D. Chung, and S.K. Das Mouse primary uterine cell coculture system revisited: ovarian hormones mimic the aspects of in vivo uterine cell proliferation Endocrinology 152 2011 3246 3258
44. K. Shoji, K. Oda, T. Kashiyama, Y. Ikeda, S. Nakagawa, K. Sone, Y. Miyamoto, H. Hiraike, M. Tanikawa, A. Miyasaka, T. Koso, Y. Matsumoto, O. Wada-Hiraike, K. Kawana, H. Kuramoto, F. McCormick, H. Aburatani, T. Yano, S. Kozuma, and Y. Taketani Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas PLoS One 7 2012 e37431
45. H. Berglind, Y. Pawitan, S. Kato, C. Ishioka, and T. Soussi Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination Cancer Biol Ther 7 2008 699 708
46. T. Fujisawa, J. Watanabe, Y. Kamata, M. Hamano, H. Hata, and H. Kuramoto VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells Hum Cell 16 2003 47 54
47. X. Wan, B. Harkavy, N. Shen, P. Grohar, and L.J. Helman Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 26 2007 1932 1940
48. E. Seront, A. Pinto, C. Bouzin, L. Bertrand, J.P. Machiels, and O. Feron PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation Br J Cancer 109 2013 1586 1592
49. Y. Kamata, J. Watanabe, H. Hata, M. Hamano, and H. Kuramoto Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines Eur J Gynaecol Oncol 25 2004 55 60
50. J.M. Park, Y. Kanaoka, N. Eguchi, K. Aritake, S. Grujic, A.M. Materi, V.S. Buslon, B.L. Tippin, A.M. Kwong, E. Salido, S.W. French, Y. Urade, and H.J. Lin Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice Cancer Res 67 2007 881 889
51. M. Nakamura, H. Tsumura, T. Satoh, K. Matsumoto, H. Maruyama, M. Majima, and H. Kitasato Tumor apoptosis in prostate cancer by PGD(2) and its metabolite 15d-PGJ(2) in murine model Biomed Pharmacother 67 2013 66 71
52. H. Onoe, R. Ueno, I. Fujita, H. Nishino, Y. Oomura, and O. Hayaishi Prostaglandin D2, a cerebral sleep-inducing substance in monkeys Proc Natl Acad Sci U S A 85 1988 4082 4086